Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma

Acta Oncologica

Volumn 52, Issue 5, 2013, Pages 963-970

  Spindler, Karen Lise G ^a   Sorensen, Morten M ^b   Pallisgaard, Niels ^a   Andersen, Rikke F ^a   Havelund, Birgitte M ^a   Ploen, John ^a   Lassen, Ulrik ^b   Jakobsen, Anders K M ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; K RAS PROTEIN; TEMSIROLIMUS; FLUOROPYRIMIDINE; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EPISTAXIS; FEMALE; FEVER; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT; ANAPHYLAXIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; DRUG DOSE REDUCTION; DRUG TOLERANCE; GENETIC ASSOCIATION; HUMAN TISSUE; OUTCOME ASSESSMENT;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84877350259     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.776175     Document Type: Article

References (23)

1. De Roock W, C laes B, B ernasconi D , De Schutter J, Biesmans B , Fountzilas , et al . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the effi cacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis . Lancet Oncol 2010; 11: 753-62 .
2. Qiu LX, M ao C, Z hang J, Z hu XD , L iao RY , X ue K, et al . Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies . Eur J Cancer 2010; 46: 2781-7 .
3. Dancey JE, C uriel R , P urvis J . E valuating temsirolimus activity in multiple tumors: A review of clinical trials . Semin Oncol 2009; 36(Suppl 3): S46-58 .
4. Zhang Y J , D ai Q , S un D F , X iong H , T ian X Q, G ao FH, et al . mTOR signaling pathway is a target for the treatment of colorectal cancer . Ann Surg Oncol 2009; 16: 2617-28 .
5. Pencreach E, G u é rin E, N icolet C, L elong-Rebel I , Voegeli AC , Oudet P , et al . Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis . Clin Cancer Res 2009; 15: 1297-307 .
6. Gulhati P , C ai Q , L i J , L iu J , R ychahou P G , Q iu S , et a l . Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer . Clin Cancer Res 2009; 15: 7207-16 .
7. Pencreach E, G u é rin E, N icolet C, L elong-Rebel I , Voegeli AC , Oudet P , et al . Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis . Clin Cancer Res 2009; 15: 1297-307 .
8. Gerullis H, E cke TH , E imer C, H euck CJ, O tto T , et al . mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: A review. Minerva Urol Nefrol 2010; 62: 411-23 .
9. Raymond E, A lexandre J, F aivre S , V era K, M aterman E, Boni J , et al . Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer . J Clin Oncol 2004; 22: 2336-47 .
10. Farag SS , Z hang S , J ansak BS, W ang X , K raut E , Chan K , et al . Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma . Leuk Res 2009; 33: 1475-80 .
11. Chan S , S cheulen M E , J ohnston S , M ross K , C ardoso F , Dittrich C , et al . Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer . J Clin Oncol 2005; 23: 5314-22 .
12. Tabernero J, R ojo F , C alvo E, B urris H, J udson I , H azell K, et al . Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors . J Clin Oncol 2008; 26: 1603-10 .
13. Chan S , S cheulen M E , J ohnston S , M ross K , C ardoso F , Dittrich C , et al . Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer . J Clin Oncol 2005; 23: 5314-22 .
14. Di Nicolantonio F, A rena S , T abernero J , G rosso S , M olinari F, Macarulla T , et al . Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus . J Clin Invest 2010; 120: 2858-66 .
15. Bianco R , G arofalo S , R osa R , D amiano V , G elardi T , Daniele G , et al . Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs . Br J Cancer 2008; 98: 923-30 .
16. Janku F , T simberidou AM , G arrido-Laguna I , W ang X , Luthra R , Hong DS , et al . PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR Axis Inhibitor . Mol Cancer Ther 2011; 10: 558-65 .
17. B ouchahda M , K araboué A , S affroy R , I nnominato P , Gorden L , Guettier C , et al . Acquired KRAS mutations during progression of colorectal cancer metastases: Possible implications for therapy and prognosis . Cancer Chemother Pharmacol 2010; 66: 605-9 .
18. Baldus SE , S chaefer KL, E ngers R , H artleb D , S toecklein NH , Gabbert HE . Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases . Clin Cancer Res 2010; 16: 790-9 .
19. Linardou H , Briasoulis E , Dahabreh I J, Mountzios G , Papadimitriou C , Papadopoulos S , et al . All about KRAS for clinical oncology practice: Gene profi le, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer . Cancer Treat Rev 2011; 37: 221-33 .
20. De Roock W , J onker D J , D i Nicolantonio F , S artore-Bianchi A , Tu D , Siena S , et al . Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab . JAMA 2010; 304: 1812-20 .
21. Lecomte T , C eze N , D orval E , L aurent-Puig P . C irculating free tumor DNA and colorectal cancer . Gastroenterol Clin Biol 2010; 34: 662-81 .
22. Yen LC, Y eh YS , C hen CW, W ang HM , T sai HL, L u CY , et al . Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer . Clin Cancer Res 2009; 15: 4508-13 .
23. Spindler KL, P allisgaard N , V ogelius I , J akobsen A . Q uantitative cell free DNA, KRAS and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan . Clin Cancer Res 2012; 18: 1177-85 .